Insulin degludec is an ultra-long-acting insulin analog developed for the study of hyperglycemia associated with type 1 and type 2 diabetes. Insulin degludec exhibits binding efficiency to the insulin receptor with an IC50 of 19.59 nM. Insulin degludec is applicable in diabetes research for evaluating pharmacological properties of basal insulin therapies.

insulin receptor:19.59 nM

Methods: HL-1 cardiomyocytes were treated with Insulin degludec (200 nM, 0-60 min), and the phosphorylation level of Akt was detected by Western blot.
Results: The phosphorylation level of Akt decreased after 5 and 10 minutes of Insulin degludec treatment. [2]

Methods: Insulin degludec (5 U/kg, once daily for 30 consecutive days) was subcutaneously administered to diabetes mellitus mice to investigate the effects of Insulin degludec on vitis vinifera glucose homeostasis and hepatic metabolism in T1D mice under IIH conditions.
Results: Insulin degludec significantly improved utetheisa kong fasting blood glucose, body weight gain, and serum AST and ALT activities in T1D mice, but exhibited a weaker response to IIH.[1]